6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $5M | -$201M | 0.0% | -4498.1% | -166.4% | -58.7% | -$167M | — | $63M |
| 2024 | $3M | -$196M | 0.0% | -6787.4% | -127.9% | -65.8% | -$130M | — | $182M |
| 2023 | $0 | -$198M | — | — | -148.9% | -102.2% | -$174M | — | $42M |
| 2022 | $0 | -$122M | — | — | -38.5% | -33.8% | -$148M | — | $188M |
| 2021 | $0 | -$165M | — | — | 105.8% | -54.8% | -$38M | — | $185M |
| 2020 | $5M | -$3M | 0.0% | -17.9% | -145.9% | — | -$6M | — | $37M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$42M | — | — | -105.8% | -16.9% | -$41M | — | $47M |
| Mar '26 | — | -$49M | — | — | -64.0% | -16.7% | -$43M | — | $64M |
| Dec '25 | $838000 | -$46M | 0.0% | -5800.5% | -38.1% | -13.4% | -$38M | — | $63M |
| Sep '25 | $1M | -$51M | 0.0% | -4406.0% | -31.3% | -13.1% | -$35M | — | $71M |
| Jun '25 | $1M | -$53M | 0.0% | -4787.2% | -86.4% | -18.8% | -$43M | — | $54M |
| Mar '25 | $1M | -$52M | 0.0% | -3603.3% | -48.5% | -15.8% | -$51M | — | $92M |
| Dec '24 | $2M | -$42M | 0.0% | -2025.7% | -27.6% | -14.2% | $14M | — | $182M |
| Sep '24 | $209000 | -$53M | 0.0% | -25948.3% | -27.7% | -15.8% | -$27M | — | $118M |
| Jun '24 | $0 | -$55M | — | — | -28.1% | -21.3% | -$47M | — | $56M |
| Mar '24 | $591000 | -$46M | 0.0% | -8179.5% | -18.8% | -14.7% | -$70M | — | $94M |
| Dec '23 | $0 | -$66M | — | — | -49.3% | -33.9% | -$46M | — | $42M |
| Sep '23 | $0 | -$51M | — | — | -26.1% | -21.2% | -$42M | — | $44M |
| Jun '23 | $0 | -$42M | — | — | -17.7% | -15.1% | -$43M | — | $121M |
| Mar '23 | $0 | -$39M | — | — | -14.1% | -12.4% | -$44M | — | $133M |
| Dec '22 | — | -$39M | — | — | -12.4% | -10.9% | -$36M | — | $188M |
| Sep '22 | — | -$29M | — | — | 13.2% | -13.6% | -$35M | — | $48M |
| Jun '22 | — | -$29M | — | — | 15.0% | — | -$25M | — | $92M |
| Mar '22 | — | -$24M | — | — | 14.3% | — | -$52M | — | $164M |
| Dec '21 | — | -$63M | — | — | 40.3% | -20.8% | -$14M | — | $185M |
| Sep '21 | — | -$16M | — | — | 17.4% | — | — | — | $201M |
How the market has priced PRME against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Prime Medicine, Inc.'s revenue has declined 2.3% per year. These are computed facts, not advice.
As of FY2025, Prime Medicine, Inc. reported — of total debt against $63M of cash.
In FY2025, gross margin was —, operating margin -4498.1%, and net margin -4342.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.